Aug 12, 2020
Immune Thrombocytopenia (ITP) Market To Reach USD 3.68 Billion By 2027 | Reports And Data
Jun 11, 2020
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
Jun 08, 2020
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 27, 2020
Immune Thrombocytopenia Market is Anticipated to Grow by 2030 Owing to a Rich and Robust Pipeline
May 05, 2020
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 30, 2020
China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Feb 27, 2020
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Feb 11, 2020
PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
Jan 13, 2020
Dova Granted Orphan Drug Designation for Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia
Jan 13, 2020
Rigel Pharmaceuticals Provides Business Update
Dec 21, 2019
FDA Grants Avatrombopag Orphan Drug Designation for the Treatment of Chemotherapy-induced Thrombocytopenia
Dec 17, 2019
Rigel Announces Chief Commercial Officer Transition
Dec 09, 2019
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Dec 09, 2019
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates
Dec 09, 2019
Doptelet ® (avatrombopag) Demonstrates Cost-effectiveness for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease
Dec 05, 2019
Data to be Highlighted at the American Society of Hematology 2019 Annual Meeting
Dec 03, 2019
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Dec 02, 2019
Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028: Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan
Nov 15, 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Nov 07, 2019
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition